This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held the top spot, the total impressions dipped by 2 million from when Sanofi ...

HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), ...

J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit generated the ...

Please provide your email address to receive an email when new articles are posted on . Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens.

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

Q1 2025 Management View CEO Joaquin Duato highlighted strong operational sales growth of 4.2% with contributions from both Innovative Medicine and MedTech segments. He emphasized the company's ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis.

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Johnson & Johnson announced that the Tremfya Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its ...

(RTTNews) - Drug major Johnson & Johnson (JNJ) announced Friday positive results from the TREMFYA (guselkumab) Phase 3b APEX study in adults living with active psoriatic arthritis or PsA ...